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INTRODUCTION
Mechanical valve thrombosis (MVT) may cause valve dys-
function, and its onset may be acute or gradual, according to
the nature of thrombi (rapid or slow growth) and involvement
of hinge point (abrupt or insidious). Edmunds defined me-
chanical valve thrombosis as a complication attributable to
any type of thrombus, without evidence of infection, attach-
ed around a mechanical valve, deranging hemodynamics, or
interfering with valvular function (1). The risk of valve throm-
bosis is highest in the tricuspid position, with reported rates
as high as 20% (2), while the incidence of left side valve
thrombosis varies from 4% to 8.6% within 5 yr of initial
valve replacement (3, 4). Eleven-year probability of prosthetic
valve thrombosis has been reported to be 0.01% to 0.02%
in the mitral or aortic position (5), and tilting disc valves
are most commonly reported in association with this com-
plication (6). Detection of valve thrombosis may be easy or
difficult, and if valve thrombosis is suspected, transthoracic
echocardiographic evaluation can be used to confirm the diag-
nosis (7). Transesophageal echocardiographic examination is
often necessary in the mitral position because of the throm-
bi involvement along the left atrial side of the sewing ring
(8). Several factors such as inadequate anticoagulation, drug
interaction, pannus overgrowth, and pregnancy have been
suggested to promote valve thrombosis (9). This analysis
was undertaken to evaluate the risk factors and outcome of
mechanical valve thrombosis in patients who had undergone
valve replacement.
MATERIALS AND METHODS
Between January 1981 and March 2006, 2,908 mechani-
cal valve replacements were performed in 2,298 patients.
Among these, 20 patients underwent surgical intervention
due to MVT. We included only surgical cases of MVT. Throm-
bosis treated by thrombolysis was excluded. Hospital records
were reviewed retrospectively, including; preoperative clini-
cal findings, initial valve procedures and etiologies, any type
of event during follow-up or anticoagulation, diagnostic
methods and characteristics of valve thrombosis, periopera-
tive management, and outcomes. Several factors were evaluat-
ed to identify risk factors of MVT development; including
sex, valve location, and number of valves replaced. 
Twenty patients presented with MVT, 6 (30%) men and
14 (70%) women. Valve replacement involved a single valve
in 13 patients (65%), and double valve replacement was done
in 7 patients (35%) (Table 1). Implanted prosthetic valves
were listed in Table 1. One patient had a history of cerebral
embolism and another patient had a history of unilateral lower
extremity edema. Left atrial appendage resection was per-
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Surgical Management of Mechanical Valve Thrombosis: Twenty-Six
Years’ Experience
In the present study, the authors investigated the management of mechanical valve
thrombosis (MVT). From January 1981 through March 2006, 2,908 mechanical valve
replacements were performed in 2,298 patients at our institution. Twenty (0.87%)
patients presented with MVT, 14 (70.0%) were women, and the mean age of the
patients was 42.0± ±14.0 (27-66) yr. Thrombosis involved mitral in 14 (70.0%), aortic
in 2 (10.0%), tricuspid/aortic in 1 (5%), and tricuspid in 3 (15%). The interval from
first operation to valve thrombosis was 121.8± ±75.4 (0.9-284.7) months. The most
frequent clinical presentation was heart failure (13/20, 65%), and predisposing
causes of MVT were: poor compliance with warfarin (7), pregnancy (5), drug inter-
action (2), and unknown (6). All 20 patients underwent valve replacement: mitral
(14, 70.0%), tricuspid (3, 15.0%), aortic (2, 10%) and tricuspid/aortic (1, 5%). One
early death occurred due to left ventricular failure, but no late mortality occurred
during 63.3± ±49.9 (0.5-165.1) months of follow-up. MVT was treated successfully,
and pregnancy and inadequate anticoagulation were found to influence the occur-
rence of this rare complication. 
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formed in 4 (20%), and the Cox-Maze procedure in 4 (20%).
The mean postoperative left ventricular ejection fraction was
57±9.3%, and the mean initial hospital stay was 16.9±6.7
days.
Anticoagulation (heparin and warfarin) was started 24 to
48 hr after all valvular procedures. Patients were discharged
with an international normalized ratio (INR) level of 2.0 to
2.5 for mitral and aortic valve replacement cases and of 2.5
to 3.0 for tricuspid valve replacement cases.
RESULTS
The mean age at MVT diagnosis was 42.0±14.0 (27-66)
yr. The distribution of MVTs according to the site of valve
implantation was as follows: 14 (70%) mitral, 3 (15%) tri-
cuspid, 2 (10%) aortic, and 1 (5%) tricuspid/aortic. Among
double-valve prosthesis recipients (7), MVTs were in a mitral
prosthesis in 3, an aortic prosthesis in 3, and in a tricuspid
prosthesis in 2. Only one case of aortic and tricuspid valve
replacement had bivalvular thrombosis.
The mean time from first valve replacement to prosthetic
valve thrombosis was 121.8±75.4 (0.9-284.7, median 96.0)
months. There was 1 early thrombosis and 19 late throm-
boses (Table 2). The mean time between the diagnosis of
MVT and surgical treatment was 22.3±42.5 days (range,
0-180 days). Eight patients (40%) underwent an emergency
or urgent operation.
The most frequent clinical presentation was congestive
heart failure (13/20, 65%). Symptoms at presentation were
dyspnea in 12 (60%) patients, cardiogenic shock in 1 (5%)
patient, and miscellaneous symptoms (myalgia, cough, or
fever) in 2 (10%) patients (Table 2). In five patients, MVT
was an incidental fortuitous echocardiographic finding (Table
2). The majority of patients (11, 55%) with MVT were of
NYHA functional class III or IV at the time of diagnosis.
The mean duration between symptom onset and surgical
treatment was 87.8±121.7 days (range, 0-365 days). Throm-
boembolism (stroke, limb or organ ischemia) occurred bet-
ween initial valve replacement and valve thrombosis in 2
(10%) patients.
MVT was diagnosed by transthoracic echocardiography
(TTE) in 13 (65%) patients, and by transesophageal echocar-
diography (TEE) in 7 (35%) patients. INR profiles when
thrombosis was diagnosed were 1.66±0.64 (1.02-2.68) for
left-sided valves and 1.42±0.53 (1.07-2.03) for tricuspid
valves. Six patients were in target INR when valve throm-
bosis occurred.
MVT occurred during pregnancy in 7 (35%) patients, and
of these, two patients had a history of denying warfarin for
fear of possible embryopathy. We classified them as poor com-
pliance category. One patient experienced thrombosis at full
term and underwent valve replacement, 2 days later she had
a normal full term baby without any adverse event. Poor
compliance with anticoagulant treatment leading to a lower
INR than recommended was responsible for MVT in another
5 (25%) patients. Adding two patients with pregnancy, poor
warfarin compliance was responsible for 7 patients (35%).
These patients skipped warfarin for no distinct reason, and
their compliances with treatment and medication were poor.
In 2 (10%) patients MVT was thought to be related to a drug
interaction, i.e., one received medication for a common cold
1 week before thrombosis detection and the other patient
had consumed nutritional supplements with or without medi-
cation. One patient with a Bjork-Shiley convexo-concave
tilting disc valve did not take any warfarin probably due to
poor compliance. He did not take medications for 285 months,
and we could not follow him up. He presented at out clinic
St. Jude bileaflet valve (St. Jude Medical, St. Paul, MN, U.S.A.), Car-
bomedics bileaflet valve (Carbomedics, Inc, Austin, TX, U.S.A.), Bjork-
Shiley tilting disc valve (Shiley, Irvine, CA, U.S.A.), Duromedics bileaflet
valve (Edwards Lifescience, Irvine, CA, U.S.A.).
Replaced valve with brand name N=20 (%)
Mitral 11 (55)
St. Jude 6
Carbomedics 2
Bjork-Shiley 2
Duromedics 1
Tricuspid 2 (10)
Carbomedics 1
Duromedics 1
Mitral and aortic 5 (25)
Carbomedics 3
St. Jude 1
Bjork-Shiley 1
Mitral and tricuspid 1 (5)
Carbomedics 1
Aortic and tricuspid 1 (5)
St. Jude 1
Table 1. Initial mechanical valve replacement
No. of patients (%)
Early thrombosis (<30 day) 1 (5)
Late thrombosis (>30 day) 19 (95)
Symptom and sign at presentation
Dyspnea 12 (60)
Shock 1 (5)
Others 2 (10)
Fortuitous 5 (25)
Table 2. Diagnosis of valve thrombosis
No. of patients (%) Trigger factor
Drug compliance 7 (35)
Pregnancy 5 (25)
Drug interaction 2 (10)
Unknown 6 (30)
Table 3. Precipitating factors of valve thrombosis380 H. Ahn, K.-H. Kim, K.C. Kim, et al.
due to cold sweating and dyspnea 3 weeks before a diagno-
sis of MVT. No specific causes were identified in 6 (30%)
patients. Possible factors precipitating MVT are listed in
Table 3. We detected valve thrombosis during follow-up
echocardiography. Pannus formation was present with throm-
bus at the time of operation in 45% (9/20) of the patients.
All patients were started on intravenous heparin. Two
(10%) of the 20 received streptokinase-based thrombolytic
therapy, but it was not successful. One patient had acute
mitral valve thrombosis, and due to hemodynamic instabil-
ity, the patient received thrombolysis. The other patient
had acute tricuspid valve thrombosis. Both were treated by
surgical intervention and have been in good physical condi-
tion until now. All patients underwent surgery under redo-
median sternotomy, consisting of mitral valve replacement
in 14 patients (70.0%), tricuspid valve replacement in 3
patients (15.0%), aortic valve replacement in 2 (10%), and
tricuspid/ aortic valve replacement in one (5%). Thrombi
were found around valve hinge points and sewing rings, and
all valves concerned were replaced other than thrombectomy.
The majority of patients underwent bileaflet mechanical valve
replacement. Only one patient received a tissue valve; she
was 65 yr at the time of diagnosis, and she was non-compli-
ant to warfarin with a frequent bleeding history. 
The aortic cross clamping time averaged 104.9±42.8 min
(range, 52-191 min), and the cardiopulmonary bypass time
was 164.6±62.7 min (range, 79-286 min). Emergent or
urgent operation was done in 8 cases (40%) due to heart fail-
ure and hemodynamic compromise. There was one operative
death (5%) due to cardiopulmonary weaning failure. Early
complications were atrial fibrillation (3), bleeding (1), vocal
cord paralysis (1), cerebral infarction (1), atrioventricular con-
duction block (1), and pneumonia (1). 
Oral anticoagulation after surgical treatment consisted of
warfarin alone in 16 (16/19, 83%) patients and a combina-
tion of warfarin and plavix in 3 (3/19, 17%) patients. The
mean hospital stay was 18.5±18.0 (range, 8-89) days, and
the mean intensive care unit stay was 3.3±2.4 days (range,
1-9) days. No late mortality or MVT recurrence occurred
over 63.3±49.9 (0.5-165.1) months of mean follow-up. A
brief summary of clinical characteristics of all patients is pro-
vided in Table 4.
DISCUSSION
Our data show that MVT is a very rare complication after
valve replacement and that its clinical manifestations are var-
ious. The time between initial valve replacement and diagno-
sis of MVT was 121.8±75.4 months, and the median was
96.0 months. In most cases, thrombosis occurred insidious-
ly; only one patient presented with acute valve thrombosis
one month after valve replacement. Durrleman et al. (10)
reported 39 cases of prosthetic valve thrombosis with a 39.0
±42.0-month mean interval of occurrence from initial oper-
ation and an in-hospital mortality of 41%. The difference
No. Sex 1st operation Thrombus 2nd operation Interval (month)
Dx to op 
(day)
Cause Age (yr)
1 F 32 MVR, TVR TV (CM) TVR (CM) 58 8 P
2 F 66 MVR MV (SJ) MVR (SJ) 1 1 P C
3 M 31 MVR MV (SJ) MVR (SJ) 3 8 U 
4 F 57 MVR MV (CM) MVR (CE) 96 1 P C
5 M 27 MVR MV (SJ) MVR (OX) 96 3 P C 
6 M 61 MVR MV (CM) MVR (SJ) 81 1 D I 
7 F 66 MVR, AVR MV (CM) MVR (OX) 173 48 D I 
8 F 47 AVR, TVR AV, TV (SJ) AVR, TVR (SJ) 167 86 U
9 F 31 MVR, AVR MV (CM) MVR (CM) 89 180 P
10* F 30 TVR TV (CM) TVR (CM) 31 1 P
11 F 54 MVR, AVR MV (BS) MVR, TVR (SJ) 84 1 U
12 M 34 TVR TV (DM) TVR (SJ) 127 1 U
13 F 43 MVR, AVR AV (CM) AVR (CM) 123 14 U
14 F 34 MVR MV (SJ) MVR (OX) 69 1 PC
15 F 38 MVR MV (BS) MVR (OX) 164 5 PC
16 F 27 MVR MV (DM) MVR (SJ) 35 12 P
17 F 61 MVR, AVR AV (SJ) AVR (SJ) 214 30 U
18 F 29 MVR MV (SJ) MVR (ET) 157 7 P
19 M 27 MVR MV (SJ) MVR (SJ) 160 24 P C
20 M 44 MVR MV (BS) MVR (OX) 285 14 P C
Table 4. Brief summary of clinical characteristics of the patients 
*, Right-sided atrioventricular valve in corrected transposition of great arteries.
Dx, diagnosis; Op, operation; AV, aortic valve; AVR, aortic valve replacement; MV, mitral valve; MVR, mitral valve replacement; TV, tricuspid valve;
TVR, tricuspid valve replacement; M, male; F, female; CM, Carbomedics; SJ, ST. Jude; DM, Duromedics; BS, Bjork-Shiley; CE, Carpentier Edwards;
OX, On-X; ET, Edwards TEKNA; P, pregnancy; P C, poor compliance; U, unknown; D I, drug interaction. Mechanical Valve Thrombosis  381
between our series and Durrleman’s data might be due to dif-
ferent patient populations. Some patients might have been
lost, and possible unknown sudden death cannot be ruled
out. Clinical course might depend on the type of replaced
valves; patients with bileaflet mechanical valves might have
had stable hemodynamics due to a well-functioning single
leaflet or have had unstable vital signs due to bileaflet involve-
ment. The fact is that the clinical manifestations of MVT
are various. 
During follow-up, we usually suspect valve thrombosis in
cases with valve click loss, skipped warfarin, newly appeared
symptoms, and so on. In the present study, TTE detected
valve thrombosis in 75% of our series, and we found inci-
dental valve thrombosis using this modality in five patients
during routine echocardiographic follow-ups. In those cases,
none had symptoms, and we could not follow with urgent
operations. Detection of valve thrombosis may be difficult,
and some series have reported that as many as 50% of cases
are diagnosed postmortem (4).
In a recent study, the delay between first onset of symp-
toms and hospitalization was found (from 1 to 45 days) (11).
Previous studies have shown that a delay in diagnosis and a
long duration of symptoms result in a higher mortality (12).
However, physical examination is an inadequate diagnostic
tool and strong clinical suspicion is the most important to
detect these complications. Any new or worsening symp-
toms in a patient with mechanical valve warrant a thorough
investigation to exclude valve thrombosis. In the present
series, MVT was diagnosed by TTE in 13 (65%) patients
and by transesophageal echocardiography in 7 (35%) patients.
During follow-up, we suggest a periodical echocardiograph-
ic examination. Early detection and diagnosis may often be
limited by a progressive or insidious course. The difference
of valve thrombosis incidence and the pattern of onset bet-
ween tilting disc and bileaflet valve is still uncertain.
Another remarkable point of the present study is that preg-
nancy and inadequate anticoagulation influenced the occur-
rence of this complication. Buttard and colleagues (11) found
inadequate anticoagulation at the time of diagnosis in 45%
of their patients: 27% for medical reasons (surgical interven-
tion, neurologic events, or pregnancy) and 17% because of
poor drug compliance. A definite relationship has already
been established between inadequate anticoagulation and
valve thrombosis (11-14). 
Anticoagulation during pregnancy is a difficult problem
to solve, as pregnancy induces various biophysiologic changes
and a hypercoagulable status. The risk of warfarinization dur-
ing pregnancy is teratogenicity, particularly between the 6th
and 12th weeks of gestation (15, 16). Therefore, it is obvi-
ous and mandatory to use anticoagulation extremely carefully
to prevent valve thrombosis or thromboembolism. Our data
also demonstrate difficulties in maintaining adequate anti-
coagulation during pregnancy; however, no safe and reliable
protocol for anticoagulation therapy during pregnancy has
been established (17).
Pannus formation, defined as excessive fibrosis around a
prosthetic valve, may occur in 25% of patients as early as
the first postoperative month (11). It plays an important role
in the mechanism of obstruction and could be the sole cause
of mechanical valve thrombosis occurrence (9). In the present
series, the precise role of pannus in the pathogenesis of valve
thrombosis remains unknown. We found pannus in 45% of
patients. However, whether it caused valve thrombosis or
not was still uncertain, so we did not include it as a cause of
valve thrombosis.
Recently, Roudaut et al. (18) conducted a retrospective
study of 110 patients treated with fibrinolytic therapy and
concluded that this treatment should be reserved for select-
ed patients (those with tricuspid thrombosis, critically ill
patients, and patients with contraindications to surgical inter-
vention). We consider that thrombolysis can be tried, espe-
cially in the tricuspid valve position. Thrombolysis appears
to be useful as a medical bridge to operation and as a major
curative modality when a patient’s medical condition or
hemodynamics is poor. In the present series, thrombolysis
was attempted in two patients, but was not successful.
The present study shows that pregnancy and inadequate
anticoagulation probably influenced the occurrence of this
rare complication. However, our knowledge of MVT is still
inadequate, and more efficient ways of eradicating this com-
plication should be suggested.
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